SCHEMBL31662089

SCHEMBL31662089

CSc1nc(NC[C@H](C)O[Si](C)(C)C(C)(C)C)c2c(OC(C)C)nc(Cl)cc2n1

nearest known ligand 0.31

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31662017 0.73 MAPK1 (0.30) L3MBTL1
SCHEMBL31662192 0.71 SMN1; SMN2 (0.35) LMNAL3MBTL1
SCHEMBL31662449 0.70
SCHEMBL31661998 0.65
SCHEMBL31662039 0.65 LMNA (0.31) LMNAL3MBTL1
SCHEMBL23908020 0.58 POLB (0.41) LMNAL3MBTL1
SCHEMBL31662081 0.57 KMT2A (0.37) LMNAL3MBTL1
SCHEMBL21203181 0.56
SCHEMBL20636583 0.56
SCHEMBL24738609 0.55 APLNR (0.30)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025151594-A1 FUSED AZINES AS RAS INHIBITORS AND METHODS OF USE THEREOF KESTREL THERAPEUTICS INC. (US) 2025-07-17 WO disclosed